The impact of bevacizumab on EGFR-TKI and anti-EGFR antibody
The impact of bevacizumab on EGFR-TKI and anti-EGFR antibody
批准号:
26893155
负责人:
Ohashi Kadoaki
金额:
$1.91万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Research Activity Start-up
财政年份:
2014
资助国家:
日本
项目状态:
已结题
起止时间:
2014-08-29 至 2016-03-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
DOI:
10.18632/oncotarget.3956
发表时间:
2015-12-15
期刊:
Oncotarget
影响因子:
--
作者:
[Galvani E, Sun J, Leon LG, Sciarrillo R, Narayan RS, Sjin RT, Lee K, Ohashi K, Heideman DA, Alfieri RR, Heynen GJ, Bernards R, Smit EF, Pao W, Peters GJ, Giovannetti E]
通讯作者:
Giovannetti E
The impact of bevacizumab on combination low-dose afatinib and cetuximab therapy in lung cancer cells harboring activated EGFR mutations
贝伐珠单抗对低剂量阿法替尼和西妥昔单抗联合治疗对携带激活 EGFR 突变的肺癌细胞的影响
DOI:
--
发表时间:
2015
期刊:
影响因子:
--
作者:
[Kenichiro Kudo, Kadoaki Ohashi, Eiki Ichihara,Toshio Kubo, Daisuke Minami, Akiko Sato,Katsuyuki Hotta, Mitsune Tanimoto, Katsuyuki Kiura]
通讯作者:
Katsuyuki Kiura
The impact of bevacizumab on combination low-dose afatinib and cetuximab therapy in lung cancer cells harboring activated EGFR mutations
贝伐珠单抗对低剂量阿法替尼和西妥昔单抗联合治疗对携带激活 EGFR 突变的肺癌细胞的影响
DOI:
--
发表时间:
2015
期刊:
影响因子:
--
作者:
[Kenichiro Kudo, Kadoaki Ohashi, Eiki Ichihara, Daisuke Minami, Hisao Kubo, Akiko Sato, Yuka Kato, Hideko Isozaki, Hiroe Kayatani, Tomoki Tamura, Mitsune Tanimoto, and Katsuyuki Kiura]
通讯作者:
and Katsuyuki Kiura
Development of a curative treatment strategy for lung cancer using the persister cancer cell mouse model.
-
批准号:19K08625
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.75万
-
财政年份:2019
-
负责人:Ohashi Kadoaki
-
依托单位:
In vivo efficacy of triplet therapy with osimertinib, cetuximab and bevacizumab for lung cancer cells harboring EGFR T790M
-
批准号:16K19454
-
项目类别:Grant-in-Aid for Young Scientists (B)
-
资助金额:$2.5万
-
财政年份:2016
-
负责人:Ohashi Kadoaki
-
依托单位:
国内基金
基于卤键设计、合成新型EGFRT790M选择性抑制剂及其抗非小细胞肺癌研究
-
批准号:81502912
-
项目类别:青年科学基金项目
-
资助金额:17.9万元
-
批准年份:2015
-
负责人:胡杰
-
依托单位: